Edition:
United Kingdom

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

10.75USD
16 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$10.75
Open
$10.70
Day's High
$10.80
Day's Low
$10.45
Volume
22,681
Avg. Vol
95,566
52-wk High
$21.35
52-wk Low
$8.62

Chart for

About

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of... (more)

Overall

Beta: 2.21
Market Cap(Mil.): $1,257.42
Shares Outstanding(Mil.): 67.79
Dividend: --
Yield (%): --

Financials

  EPZM.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -2.06 -- --
ROI: -51.70 1.78 14.61
ROE: -59.18 3.28 16.33

BRIEF-Epizyme Reports Q1 Loss Per Share Of $0.49

* EPIZYME REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

08 May 2018

BRIEF-Epizyme Provides Update Regarding Tazemetostat Clinical Program

* EPIZYME PROVIDES UPDATE REGARDING TAZEMETOSTAT CLINICAL PROGRAM

23 Apr 2018

BRIEF-Epizyme Inc Files For Potential Mixed Shelf, Size Not Disclosed

* EPIZYME INC FILES FOR POTENTIAL MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING Source text: (https://bit.ly/2q8HM38) Further company coverage:

05 Apr 2018

BRIEF-Epizyme Q4 Loss Per Share $0.52

* EPIZYME REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND 2018 MILESTONES

13 Mar 2018

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥9,569 -166.00
Novartis AG (NOVN.S) CHF82.42 +0.70
GlaxoSmithKline plc (GSK.L) 1,608.00 -2.00
Celgene Corporation (CELG.OQ) $89.90 -0.25

Earnings vs. Estimates